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A B S T R A C T
Introduction: Deep vein thrombosis (DVT) originates in the valvular sinuses of large veins in a local milieu
characterized by stasis and severe hypoxia. This may induce complement- and coagulation activation, which
potentially increases the risk of venous thromboembolism (VTE). The aim of the present study was to investigate
whether the activity of the complement pathways, the level of mannose-binding lectin (MBL) and tissue-factor
(TF) induced thrombin generation were associated with risk of unprovoked VTE.
Methods: A case-control study was performed in patients with unprovoked VTE (n= 24) and age- and sex-
matched healthy controls (n=24). Serum complement pathway activity was measured by the total complement
screen assay (Wieslab®). MBL was quantified by ELISA. Plasma TF-induced thrombin generation was measured
using the CAT-assay.
Results: Activity in the highest quintile of the classical pathway was associated with increased odds of un-
provoked VTE (OR 4.5, 95% CI; 0.8–24.7). Moreover, MBL deficiency (≤100 ng/ml) was associated with un-
provoked VTE (OR 3.5, 95% Cl; 0.8–15.3). VTE patients had shortened TF-induced lag-time (4.8 ± 0.6min vs.
5.8 ± 2.1min, p < 0.001) and a higher endogenous thrombin potential (ETP) (1383 ± 267 nM∗h vs.
1265 ± 247 nM∗h, p=0.07) than controls. No association between the classical complement pathway activity
or MBL deficiency, and parameters of TF-induced thrombin generation was observed.
Conclusion: Our findings suggest that high activity of the classical complement pathway, and MBL deficiency,
might be associated with an increased odds of unprovoked VTE, independent of activation of TF-induced coa-
gulation.
1. Introduction
Venous thromboembolism (VTE) is a common disease with a com-
plex, multicausal etiology accompanied by serious short- and long-term
complications, including death [1]. Virchow's triad, which includes
vessel wall damage/dysfunction, changes in blood flow/stasis, and
hypercoagulability, represents the key elements in the pathogenesis of
thrombosis [2]. Autopsy- [3] and imaging [4] studies suggest that
formation of venous thrombi originate in the valvular sinuses of large
veins. The milieu in the valvular sinuses is characterized by severe
hypoxia and stasis [5], conditions known to induce cellular immune
responses [6]. Although the incidence of arterial cardiovascular dis-
eases, e.g. myocardial infarction and stroke, have declined by 25–40%
during the last two decades [7], the incidence of VTE remains stable or
has even increased during the same time period [8]. In order to reduce
the incidence of VTE, it is necessary to discover disease mechanisms
that could be targets for future prevention and treatment.
The complement system is an important part of the innate immune
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system [9]. Studies suggesting that complement is activated by hypoxic
cells and tissues [10], make it reasonable to assume that complement is
also activated in the hypoxic milieu in the valvular sinuses. Results from
observational and animal studies suggest that the complement system is
involved in the early steps in the pathogenesis of VTE. In a large po-
pulation-based cohort study, subjects with plasma complement C3
concentration in the highest tertile had 31% higher risk of VTE com-
pared to those in lowest tertile [11]. C3-deficient mice had lower in-
cidence of venous thrombosis and reduced thrombus size compared to
wild-type mice in a tissue factor (TF)-dependent model of flow-re-
striction induced venous thrombosis [12]. Further, in a cross-sectional
study of patients with systemic lupus erythematosus (SLE), patients
with a previous history of VTE showed increased deposition of com-
plement factors C1q, C4 and C3 on platelets [13].
TF-induced thrombin formation in plasma ex vivo, i.e. the cali-
brated automated thrombogram (CAT), is proved useful in assessing
thrombosis risk [14, 15]. The CAT displays thrombin activity over time
in clotting plasma and allows for assessment of the initiation phase (lag
time) and propagation phase (endogenous thrombin potential-ETP) of
coagulation. Parameters of the thrombogram (e.g. lag time and ETP)
are associated with risk of incident [16] and recurrent VTE [17].
The complement system can be initiated by three pathways de-
pending on stimuli: classical, alternative and lectin [18]. These can be
evaluated based on specific activation stimuli ending with the terminal
pathway as a common readout [19]. Even though there is growing
evidence for a role of the complement system in the pathogenesis of
VTE, it is not known which pathways of the system that are involved,
and to what extent the activity of the different complement pathways
are associated with known risk factors of VTE, such as parameters of the
thrombogram. Complement deficiencies, as detected by abolished ac-
tivity in one or several of the pathways, are extremely rare, except for
the lectin pathway mannose binding lectin (MBL) molecule. Mannose-
binding lectin (MBL) is a C-type lectin that plays an important role in
innate immunity. MBL binds to repetitive carbohydrate patterns, such
as mannose, on foreign pathogens and altered host cells, to promote
opsonophagocytosis and activation of the lectin pathway of the com-
plement system [18, 20]. Around 5–20% of the population is classified
as MBL-deficient according to a cut-off level of< 100 ng/ml. However,
this cut-off level is disputed due to high rates of haplotype variation
[21–23]. In addition to the general activity of the three complement
pathways, we therefore also measured the levels of MBL.
In the present study, we aimed to investigate whether activity of the
various complement pathways and levels of MBL were (i) associated
with VTE risk and (ii) correlated with TF-induced thrombin generation
in plasma. To address these questions, we performed a case-control
study in patients with a previous history of unprovoked VTE and po-
pulation-based controls.
2. Material and methods
2.1. Study population
Patients with unprovoked VTE were recruited from the fourth
survey of the Tromsø Study (conducted in 1994–95), a single-center
prospective, population-based study, with repeated health surveys of
inhabitants of Tromsø, Norway [24]. A VTE case in this registry had all
of the following criteria fulfilled; (1) objectively confirmed by diag-
nostic procedures, (2) the medical record indicated that a physician had
made a diagnosis of DVT and/or PE, (3) signs and symptoms consistent
with DVT or PE were present, and (4) therapy with anticoagulants
(heparin, warfarin, or a similar agent), thrombolytics, or vascular sur-
gery was initiated. Unprovoked VTE was defined as complete absence
of provoking factors at the time of diagnosis. Provoking factors were
defined as recent surgery or trauma (within 8 weeks before the event),
an acute medical condition (myocardial infarction, ischemic stroke,
major infectious disease), cancer, marked immobilization (bed rest >
3 days, confinement to wheelchair, long-distance travel > 4 h within
the last 14 days), pregnancy or puerperium, estrogen supplementation,
or another likely provoking factor specifically described by a physician
in the medical record (e.g., intravascular catheter).
VTE cases were recruited from a general population health survey
(the fourth Tromsø Study) and invited to participate in an additional
screening visit. VTE cases were eligible for the current study if they
were between 20 and 80 years of age, had an unprovoked VTE event
without recurrence 1 to 6 years before inclusion (i.e. blood sampling),
had discontinued anticoagulant treatment at least 3 months before the
blood samples were collected, and did not have any other medical
conditions (e.g. cancer and auto-inflammatory diseases). For each VTE
case, one healthy person matched for age and sex was recruited from
the fourth Tromsø Study and underwent the same screening visit and
blood sampling as the VTE patients [25].
Complete medical history, physical examination, and blood samples
were obtained for VTE cases and controls. Details on the occurrence of
cardiovascular events, including previous or current transient ischemic
attacks, stroke, angina pectoris, and MI, and recurrent venous throm-
bosis, diabetes mellitus, and other concurrent diseases was obtained
with a self-administrated questionnaire that also included dietary ha-
bits, physical exercise, and alcohol consumption. Height and weight
were measured with the participants in light clothing without shoes.
Body mass index (BMI) was calculated as the weight in kilograms di-
vided by the square of height in meters (kg/m2).
Measurements of protein C, protein S and antithrombin were de-
termined by commercially available assays obtained from Diagnostica
Stago® (Parsippany, New Jersey, USA) and preformed according to the
manufactures instructions. Screening for factor V Leiden and factor II
G20210A mutations was carried out on genomic DNA as previously
described [26]. Measurements of white blood cells, platelets and he-
moglobin were performed with the ABX Micros 60 cell counter
(HORIBA ABX SAS, Kyoto, Japan).
2.2. Blood collection and storage
Blood was drawn from an antecubital vein in the morning at
7:45 a.m. after 12 hour overnight fasting and 48 hour refrain of ex-
haustive physical exercise and alcohol consumption. Serum was pre-
pared by clotting whole blood in a glass tube at room temperature for
1 h. Blood for plasma preparation was collected into 4.5ml vacutainers
(Becton Dickinson, Meylan Cedex, France) containing 0.129M sodium
citrate (1 vol anticoagulant and 9 vol whole blood) as anticoagulant.
Serum and plasma were prepared by centrifugation at 2000g for 15min
at 22 °C, transferred into cryovials (Greiner laboratechnik, Nürtringen,
Germany) in aliquots of 1ml and stored at −70 °C until further ana-
lysis.
2.3. Calibrated Automated Thrombinoscope
Thrombin generation was assessed using a CAT and was performed
as described by Hemker et al. [14] and according to the manufacturer's
instructions (Thrombinoscope BV, Maastricht, the Netherlands).
Thrombin generation was measured in a Fluoroscan Ascent Fluo-
rometer (Thermolabsystems OY, Vantaa, Finland) equipped with a
dispenser. Fluorescence intensity was detected at wavelengths of
355 nm (excitation filter) and 460 nm (emission filter). Briefly, 80 μl of
the plasma samples were dispensed into the wells of round bottom 96-
well microtiter plates (Immulon, Lab Consult, Lillestrøm, Norway).
Twenty μl of a mixture containing TF (Innovin, Bade Behring) and
phospholipids (PL) (Cephaline, from rabbit brain) was added to the
plasma samples to obtain a final concentration of 5 pM and 4 μM, re-
spectively. For each experiment, a fresh mixture of 2.5mM fluorogenic
substrate (Z-Gly-Gly-Arg-AMC from Bachem, Bubendorf, Switzerland)
and 0.1M CaCl2 was prepared using buffer containing 20mM Hepes
(Sigma Aldrich, St Louis, USA) and 60mg/ml BSA (A-7030, Sigma
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Aldrich) with pH 7.35. The calibrator with thrombin activity of 600 nM
was obtained from Thrombinoscope BV (Maastricht, The Netherlands).
The thrombin calibrator corrects for donor-to-donor differences in color
of plasma and inner filter effect [27]. The computer software calculated
lag time (min), the time to peak (min), the peak of thrombin generation
(nM) and the area under the thrombin generation curve (nM∗min) or
endogenous thrombin potential (ETP).
2.4. Assessment of complement pathway activity in human serum samples
The activity of the classical, alternative and lectin pathways of the
complement system was assessed by a commercially available assay
(Wielisa COMPL300 Total Complement Functional Screen kit from
Wieslab AB, Lund, Sweden) and conducted according to the instructions
provided in the manual. In brief, strips of wells for classical pathway
(CP) evaluation were pre-coated with IgM, strips for alternative
pathway (AP) determination were coated with LPS, and lectin pathway
(LP) strips were coated with mannan. Sera were diluted in specific
buffers (1/101 for the CP and LP assays, and 1/18 for the AP assay), and
were incubated for 1 h at 37 °C. After washing the strips, alkaline
phosphatase-conjugated antihuman C5b-9 was added before incubation
at room temperature for 30min. Additional washing was performed,
substrate was added, and the wells were incubated for 30min. Finally,
absorbance values were read at 405 nm.
In each assay, standard positive and negative control serum pro-
vided in the kit were reconstituted with distilled water. The positive
serum was a pool of five sera from healthy individuals, and the negative
control consisted of heat-inactivated sera (56 °C for 20min).





mean A405 (sample) mean A405 (negative control)
mean A405 (standard serum) mean A405 (negative control)
100%
Samples as well as standard serum and negative control serum were
tested in duplicates at a fixed dilution. All complement activity values
are provided as % of activity in pooled normal serum. The assay is
designed as a screening assay to detect deficiencies in the various
complement pathways. It is not suitable to detect in vivo activation, but
reflects the total activity potential that could be activated within each
complement pathway in vitro [19].
2.5. Measurement of serum mannose binding lectin (MBL)
Measurement of serum concentrations of MBL was performed using
an MBL ELISA kit (BIOPORTO Diagnostics A/S, Hellerup, Denmark)
according to the manufacturer's instructions.
2.6. Statistics
The Pearson's correlation coefficient was used to test for correlation
between variables. Differences between groups with regard to com-
plement pathway activity and parameters of the thrombogram were
tested with Student's t-test for independent samples. Logistic regression
models were used to determine odds ratio (OR) per 1 standard devia-
tion (SD) increase and to determine OR of VTE in extreme categories
(highest and lowest quintiles/quartiles) of the complement pathways
activity and thrombogram parameters, respectively, compared to all
other categories. Statistical analyses were performed using SPSS for
Windows, version 22.0 (SPSS Inc. Chicago, IL, USA) and GraphPad
Prism version 5.04 for Windows (GraphPad Software, San Diego, CA,
USA). p-Values< 0.05 were considered statistically significant. The
measurements of complement pathway activities were visually in-
vestigated for normal distribution, and found satisfactory. To analyze
the correlation between high activity of the three complement path-
ways and odds of unprovoked VTE, the pathway activities was divided
in to quintiles.
3. Results
We included 24 patients with unprovoked VTE and 24 age- and
gender-matched healthy controls recruited from the general population.
For cases, the timing between the VTE event and blood sampling is
displayed in Supplementary Fig. 1. Baseline characteristics are shown in
Table 1. Except for protein C concentration, which was higher in cases
than in controls (108 ± 22% vs. 93 ± 21%, p=0.02), there were no
significant differences between the groups (Table 1).
The activity of complement pathways and the corresponding ORs of
unprovoked VTE are displayed in Table 2. The complement activity of
both the classical and the alternative pathways was detectable in serum
for all study participants, with median pathway activity above 100% in
both cases and controls (Table 2). In contrast, a number of both VTE
patients (n=10) and healthy controls (n= 5) had undetectable lectin
pathway activity, consistent with the high frequency of MBL deficiency
in the population. With a threshold level of normal lectin pathway
activity set at 10% [19], 42% of VTE patients and 21% of controls had
undetectable lectin pathway activity. VTE patients with classical
pathway activity in the highest quantile had a higher odds of un-
provoked VTE compared to subjects in the lower quantiles (OR 4.5,
95% CI 0.8–24.7). The OR of VTE was 3.5 (95% CI 0.8–15.3) for
MBL < 100 ng/ml compared to MBL > 100 ng/ml. Moreover, low
activity of the lectin pathway (< 10%) was associated with unprovoked
VTE (OR 2.7, 95% CI 0.8–9.8). As expected, lectin pathway activity and
MBL concentration was highly correlated (r= 0.9, p < 0.0001). For
the alternative pathway, neither total pathway activity nor levels of
pathway activity were associated VTE risk. Activity of the classical and
alternative pathway was, as expected, significantly correlated (r= 0.7,
p < 0.0001), whereas no correlation was found between the classical
pathway and MBL (r=−0.13, p= 0.4). Finally, there was no differ-
ence in the activity of the classical pathway in subjects without and
with MBL deficiency (Fig. 1).
Parameters of the TF-induced thrombin generation curve and their
OR for unprovoked VTE are shown in Table 3. VTE patients presented
an increased ability to generate thrombin, characterized by a shortened
lag time and time to peak, and an increased peak thrombin con-
centration and endogenous thrombin potential (Table 3, Fig. 2). One
standard deviation prolongation of lag time (1.74 min) was associated
with an OR of 0.4 (95% CI 0.2–0.8), whereas VTE patients with lag time
in the upper quartile had a OR of 0.05(95% CI 0.01–0.44). Lag time and
time to peak were strongly correlated (r= 0.9 p < 0.001) and dis-
played a similar risk pattern for VTE. One SD increase in ETP
(263.4 nM∗h) yielded an OR of 1.8 for VTE (95% CI 0.9–3.5), whereas
Table 1
Characteristics of patients with a previous history of unprovoked venous
thromboembolism (VTE) and healthy age- and sex-matched controls recruited
from a general population. Values are means ± 1 standard deviation (SD) or






Age (years) 54 ± 16 54 ± 16 0.96
Female sex 58 (14) 58 (14) 1.00
BMI (kg/m2) 28.3 ± 4.4 26.3 ± 3.9 0.10
Smoking (%) 33 (8) 17 (4) 0.18
Inherited thrombophilia
FV-Leiden (heteroz.) (%) 13 (3) 4 (1) 0.30
FII G20210A (heteroz.) (%) 4 (1) 0 (0) 0.31
Protein-C (value in %) 108 ± 22 93 ± 21 0.02
Protein-S (value in %) 101 ± 18 94 ± 19 0.16
Antithrombin (%) 102 ± 9 104 ± 8 0.37
Family history of VTE (%) 21 (5) 13 (3) 0.44
Hematological variables
Hemoglobin (g/dl) 14.4 ± 1.2 14.3 ± 1.2 0.91
White blood cells (×109/l) 6.7 ± 1.9 5.8 ± 1.5 0.10
Platelets (×109/l) 251 ± 64 247 ± 54 0.81
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ETP in the upper quartile was associated with an OR of 2.5 (95% CI
0.6–9.8).
Associations between parameters of the thrombogram across cate-
gories of complement pathway activities and MBL levels were evaluated
for the whole study population (n=48) (Table 4). There were no as-
sociation between categories of the classical- and lectin pathways and
parameters of the thrombogram. The activity of the alternative pathway
was, however, significantly correlated with both peak thrombin gen-
eration and ETP (r= 0.5, p < 0.01 and r= 0.4, p < 0.01, respec-
tively), and peak thrombin generation and ETP increased significantly
across quintiles of the alternative pathway (Table 4).
4. Discussion
In the present case-control study, we investigated the association
between activities of complement pathways, thrombin generation and
VTE risk. In accordance with previous findings [28], we found that
parameters of the thrombogram, lag time in particular, were associated
with increased odds of VTE. Cases with unprovoked VTE had higher
odds of activity levels within the highest quintile of the classical
pathway. Moreover, low lectin pathway activity, as well as MBL defi-
ciency, was associated with increased odds of VTE. There was no
association between activities of the classical- and lectin pathways and
parameters of the thrombogram. Our results suggest that the classical
pathway of the complement system and MBL deficiencies with low
lectin pathway activity might be associated with risk of VTE by me-
chanisms not mediated by an interplay with TF-induced thrombin
generation.
Several studies have shown that parameters of the thrombogram are
associated with both first and recurrent VTE [16, 17]. In the Leiden
thrombophilia study (LETS) including 360 VTE patients and 404 con-
trols, elevated ETP (> 90% percentile) was associated with a 1.7-fold
higher odds of first unprovoked VTE [29]. Similarly, subjects with peak
thrombin levels in the highest quartile had a 1.8-fold higher odds of
VTE in a nested case-control study from the Longitudinal Investigation
of Thromboembolism Etiology (LITE) including 434 cases and 1004
controls [28]. Accordingly, we found that cases with unprovoked VTE
had an almost 2-fold higher odds of having ETP levels in the highest
quartile. In addition, we found that lag time and time to peak were
shorter in patients with unprovoked VTE, suggesting that both the in-
itiation phase (lag time) and propagation phase (ETP) of coagulation
are disturbed in subjects who have experienced a VTE event.
MBL deficiency is frequent in humans, ranging up to 20–30% when
including those with levels below 400–500 ng/ml [21]. Plasma levels of
MBL are independent of sex, remain stable throughout life, and varies
mainly due to genotype [30, 31].Whereas most individuals with low
MBL are healthy, deficiency has been reported to be associated with
various autoimmune [32, 33] and infectious disorders [34, 35]. Con-
flicting results have, however, been published regarding the association
between MBL deficiency and risk of cardiovascular diseases. In a nested
case-control study including 946 cases who experienced a myocardial
infarction (MI) or died of cardiovascular diseases (CAD) and 1799
matched controls, men with MBL levels in the highest quartile had a
1.6-fold higher risk of CAD than those in the lowest quartile after ad-
justment for traditional cardiovascular risk factors. In women, no such
relation was observed [36]. In contrast, results from a case-control
study, derived from the HUNT study including 370 young (< 62 years)
MI patients and 370 age-matched controls, showed that variant hap-
lotypes causing MBL deficiency were associated with a 2-fold higher
risk of MI [37]. Several lines of evidence support a relation between
MBL deficiency and risk of cardiovascular diseases. First, MBL deficient
mice have larger atherosclerotic lesions [38] and MBL deficiency in
humans is associated with risk of severe atherosclerosis in young sub-
jects [39]. Second, MBL deficiency is associated with increased and
delayed clearance of postprandial lipidemia which is known to augment
Table 2
Complement pathway activity and serum levels of mannose binding lectin (MBL) in patients with previous unprovoked venous thromboembolism (VTE) and age- and
sex-matched healthy controls with corresponding odds ratios (OR) with 95% confidence intervals (95% CI) of VTE in linear and stratified analyses. Values are
means ± 1 standard deviation or percentages with numbers in parentheses.
Cases (n= 24) Controls (n=24) OR (95% CI) OR (95% CI)b
Classical pathway (%)
Pathway activity 112 ± 14 109 ± 13 1.30 (0.72–2.40)a 1.25 (0.68–2.30)a
Quintile 1≤ 103 25.0 (6) 16.7 (4) 1.67 (0.40–6.87) 1.86 (0.40–8.51)
Quintile 5≥ 122 29.2 (7) 8.3 (2) 4.53 (0.83–24.7) 3.39 (0.58–19.96)
Alternative pathway (%)
Pathway activity 131 ± 64 107 ± 66 1.16 (0.65–2.01)a 1.19 (0.45–3.11)a
Quintile 1≤ 71 16.7 (4) 25.0 (6) 0.60 (0.15–2.47) 0.67 (0.13–3.55)
Quintile 5≥ 197 20.8 (5) 16.7 (4) 1.32 (0.31–5.65) 1.11 (0.22–5.60)
Lectin pathway (%)
Pathway activity 60 ± 64 77 ± 54 0.86 (0.5–1.52)a 0.83 (0.45–1.51)a
Pathway activity level≤ 10 41.7 (10) 20.8 (5) 2.71 (0.76–9.78) 3.51 (0.89–13.89)
MBL level (ng/ml)
Total 412 ± 670 483 ± 610 0.82 (0.46–1.50)a 0.77 (0.40–1.49)a
≤100 33.3 (8) 12.5(3) 3.50 (0.80–15.34) 4.65 (0.96–22.42)
≤400 50.0 (12) 33.3 (8) 2.00 (0.62–6.42) 2.16 (0.64–7.31)
a OR for VTE per SD increase.
b Adjusted for age, sex and BMI.























Fig. 1. Dot-plot showing the activity of the classical complement pathway
sorted by mannose binding lectin (MBL) deficiency (MBL < 100 ng/ml). Lines
are means with standard deviations.
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atherosclerosis formation [40]. Third, MBL deficiency may promote
plaque formation by reduced ability to remove apoptotic cells [41] with
subsequent increased proatherogenic inflammation.
Previously, two smaller studies have investigated the association
between genotypes associated with MBL deficiency and risk of VTE in
patients with systemic lupus erythematosus (SLE). In a cohort of 91 SLE
patients followed for a median of 9.1 years, 14 patients developed VTE
which was unrelated to the MBL genotype [42]. In a cross-sectional
study including 114 SLE patients, the prevalence of VTE was higher in
subjects with MBL-deficient genotypes, most probably due to the co-
existence with anti-phospholipid syndrome [43]. To the best of our
knowledge, no study has investigated the prevalence of MBL deficiency
in VTE patients and controls recruited from the general population. In
our case-control study, cases had 3.5-fold higher odds of MBL defi-
ciency (≤100 ng/ml) than controls. The MBL levels were strongly
correlated with lectin pathway activity, and similarly to MBL levels, low
lectin pathway activity showed a trend towards an increased risk of
VTE. There was no correlation between low lectin pathway activity
levels/ MBL deficiency and high activity in the classical pathway,
Table 3
Parameters of tissue-factor (TF)-induced thrombograms in patients with previous unprovoked venous thromboembolism (VTE) and healthy age- and sex-matched
controls with corresponding odds ratios (OR) with 95% confidence intervals (95% CI) of VTE in linear and stratified analyses. Values are means ± 1 standard
deviation or percentages with numbers in parentheses.
Cases (n= 24) Controls (n= 24) OR (95% CI) OR (95% CI)b
Lag time (min)
Total 4.9+−0.6 6.5+−2.1 0.19 (0.06–0.68) 0.18 (0.05–0.67)a
Quartile 1≤ 4.5 29.2 (7) 20.8 (5) 1.56 (0.42–5.86) 1.62 (0.41–6.43)
Quartile 4≥ 6.1 4.2 (1) 45.8 (11) 0.05 (0.01–0.44) 0.05 (0.01–0.45)
Time to peak (min)
Total 8.5+−1.1 10.9+−3.5 0.22 (0.06–0.77)a 0.21 (0.06–0.75)a
Quartile 1≤ 8.1 41.7 (10) 20.8 (5) 2.71 (0.76–9.73) 3.18 (0.80–12.71)
Quartile 4≥ 9.8 8.3 (2) 41.7 (10) 0.13 (0.02–0.67) 0.10 (0.02–0.58)
Peak (nM)
Total 195+−37 161+−50 2.46 (1.15–5.23)a 2.75 (1.10–6.87)a
Quartile 1≤ 151 12.5 (3) 37.5 (9) 0.24 (0.06–1.03) 0.23 (0.05–1.17)
Quartile 4≥ 200 29.2 (7) 20.8 (5) 1.56 (0.42–5.86) 1.41 (0.31–6.30)
ETP (nM∗h)
Total 1402+−267 1267+−247 1.81 (0.92–3.56)a 1.73 (0.83–3.60)a
Quartile 1≤ 1159 20.8 (5) 29.2 (7) 0.64 (0.17–2.39) 1.07 (0.23–4.99)
Quartile 4≥ 1466 33.3 (8) 16.7 (4) 2.50 (0.64–9.82) 2.57 (0.56–11.68)
a OR for VTE per SD increase.










































Fig. 2. Dot-plots showing lag time (min) (panel A) and endogenous thrombin
potential (ETP) (panel B) of tissue-factor induced thrombograms in VTE cases
and controls. Lines are means with standard deviations.
Table 4
Associations between categories of various complement pathway activities and
parameters of the TF-induced thrombograms. Values are means ± 1 standard
deviation.
Lag time (min) Time to peak
(min)
Peak (nM) ETP (nM∗h)
Classical pathway (% activity)
Quintile 5≥ 122 5.2 ± 0.7 9.0 ± 1.3 195 ± 29 1416 ± 93
Quintile 1–2≤ 108 5.0 ± 2.2 8.7 ± 3.7 173 ± 47 1291 ± 257
p-Value 0.52 0.33 0.05 0.22
Alternative pathway (% activity)
Quintile 5≥ 197 5.3 ± 1.1 9.3 ± 1.9 219 ± 48 1536 ± 341
Quintile 1–2≤ 89 4.9 ± 0.9 8.8 ± 1.1 174 ± 27 1252 ± 185
p-Value 0.16 0.095 0.004 0.0004
Lectin pathway (% activity)
Pathway
activity≥ 10
5.8 ± 1.9 9.8 ± 3.2 183 ± 52 1291 ± 249
Pathway
activity≤ 10
5.4 ± 1.4 9.4 ± 2.1 189 ± 32 1350 ± 298
p-Value 0.43 0.70 0.74 0.66
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indicating that MBL deficiency in itself might be associated with risk of
VTE. The underlying mechanisms for the possible association between
MBL deficiency and VTE risk is unknown, but may be explained by the
fact that individuals with MBL deficiency are predisposed to auto-
immune- [33, 44] and infectious disease [35, 45], both of which are
associated with risk of VTE [46, 47]. Additionally, the lectin pathway
and MBL associated serine protease (MASP-1) has been shown to be a
significant contributor to coagulation in a mouse model with occlusive
thrombosis [41]. However, due to lack of association between MBL
deficiency and parameters of the thrombogram, our findings suggest
that, the trend towards increased odds of VTE in individuals with MBL
deficiency is not mediated by an effect on TF-induced coagulation ac-
tivation.
In a case-control study including 69 SLE patients and 69 age- and
sex-matched controls, the SLE patients displayed increased deposition
of C1q, C3d and C4d on platelets compared to controls patients [13].
Furthermore, the SLE patients with a history of VTE had an increased
deposition of C1q, C3, and C4d on platelets compared to SLE patients
without VTE, suggesting that activation of the classical pathway of the
complement system may play a role in the pathogenesis of VTE among
SLE patients. Accordingly, we found an OR of 4.5 for the association
between high serum activity of the classical pathway and unprovoked
VTE. However, due to the small number of participants in each quintile
in our study the results were not statistical significant and should
therefore be interpreted with caution. Since thrombin is known to ac-
tivate C3 of the complement pathway [48], one possible explanation for
the association between high complement activity and VTE could be
hypercoagulability. However, in our study we found that high activity
of the classical complement pathway was not associated with para-
meters of TF-induced thrombin generation. This indicated that the as-
sociation between activity of the complement cascade and VTE risk was
independent of coagulation parameters. The possible association be-
tween high classical pathway activity and increased VTE risk might be
explained by the hypoxic state found in the vein, particularly in the
deepest recess of the valvular sinus, where the thrombus forms [49, 50].
Hypoxia has been found to activate the complement system [10] and re-
oxygenation of hypoxic HUVEC cells incubated with 30% serum leads
to activation of the classical pathway and thus C3 depositions on cells
[51]. In our study, the activity of the classical pathway of the com-
plement system was not associated with parameters of the TF-induced
thrombogram, suggesting that the impact of the classical pathway of
the complement system is not mediated by a direct effect on coagula-
tion activation.
To the best of our knowledge, no study has investigated the re-
lationship between the activity of the alternative pathway and VTE risk.
Although we found an association between the activity of the alter-
native pathway and parameters of thrombin generation (lag time and
ETP), activity of the alternative pathway was not associated with risk of
VTE. The alternative pathway is continuously undergoing a low-grade
activation and functions as an amplifier of other routes of complement
activation [52]. Measurements of activation products of the classical
and alternative pathway in blood could shed additional light on the
mechanisms of complement activation in VTE.
Strengths of our study include the recruitment of VTE patients from a
population-based cohort and age- and sex-matched apparently healthy
controls from the same source population. In order to minimize the effect
of the acute VTE on the measurements of interest (reverse causation), all
samples were collected more than one year after the VTE event. However,
the fact that blood samples were collected after unprovoked VTE makes it
impossible to affirm the direction of the association between exposure
(activities of complement pathways) and outcome (VTE). Another lim-
itation of this study is the low number of participants included with a
considerable risk of statistical type 1 and 2 errors. Statistical analysis of
such a small sample size has limitations, and the results should be in-
terpreted with caution. Thus, a larger, prospective study should be con-
ducted to validate our findings. Due to the explorative nature of the study,
we did not adjust for multiple testing, which imply that some of the
significant associations may occur by chance.
In conclusion, results from our case-control study suggest that low
activity of the lectin pathway, reflected by MBL deficiency, and high
activity of the classical pathway might be associated with risk of un-
provoked VTE. These findings are hypothesis generating and ex-
ploratory, and a larger prospective study is warranted to validate our
findings.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.thromres.2018.06.019.
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